Kaveri Pohlman
Stock Analyst at Clear Street
(0.18)
# 4,327
Out of 4,981 analysts
22
Total ratings
14.29%
Success rate
-31.89%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kaveri Pohlman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVBP ArriVent BioPharma | Initiates: Buy | $32 | $19.69 | +62.52% | 1 | Jun 25, 2025 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $1.59 | - | 4 | Aug 1, 2024 | |
| GMAB Genmab | Maintains: Buy | $46 → $47 | $27.82 | +68.94% | 3 | Jun 27, 2024 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $20 → $30 | $6.53 | +359.42% | 2 | Apr 17, 2024 | |
| XNCR Xencor | Maintains: Buy | $56 → $38 | $8.60 | +341.86% | 1 | Apr 16, 2024 | |
| NUVB Nuvation Bio | Upgrades: Buy | $5 | $3.14 | +59.24% | 2 | Mar 26, 2024 | |
| JANX Janux Therapeutics | Initiates: Buy | $62 | $24.05 | +157.80% | 1 | Mar 21, 2024 | |
| PYXS Pyxis Oncology | Initiates: Buy | $8 | $1.82 | +339.56% | 1 | Feb 9, 2024 | |
| EXEL Exelixis | Initiates: Buy | $27 | $39.15 | -31.03% | 1 | Dec 19, 2023 | |
| RCUS Arcus Biosciences | Reiterates: Buy | $70 | $11.52 | +507.64% | 1 | Aug 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.92 | +525.00% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $8 | $2.00 | +300.00% | 2 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12,320 → $4,928 | $5.90 | +83,425.42% | 2 | Feb 9, 2022 |
ArriVent BioPharma
Jun 25, 2025
Initiates: Buy
Price Target: $32
Current: $19.69
Upside: +62.52%
MacroGenics
Aug 1, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.59
Upside: -
Genmab
Jun 27, 2024
Maintains: Buy
Price Target: $46 → $47
Current: $27.82
Upside: +68.94%
Cullinan Therapeutics
Apr 17, 2024
Maintains: Buy
Price Target: $20 → $30
Current: $6.53
Upside: +359.42%
Xencor
Apr 16, 2024
Maintains: Buy
Price Target: $56 → $38
Current: $8.60
Upside: +341.86%
Nuvation Bio
Mar 26, 2024
Upgrades: Buy
Price Target: $5
Current: $3.14
Upside: +59.24%
Janux Therapeutics
Mar 21, 2024
Initiates: Buy
Price Target: $62
Current: $24.05
Upside: +157.80%
Pyxis Oncology
Feb 9, 2024
Initiates: Buy
Price Target: $8
Current: $1.82
Upside: +339.56%
Exelixis
Dec 19, 2023
Initiates: Buy
Price Target: $27
Current: $39.15
Upside: -31.03%
Arcus Biosciences
Aug 23, 2023
Reiterates: Buy
Price Target: $70
Current: $11.52
Upside: +507.64%
Aug 31, 2022
Initiates: Buy
Price Target: $12
Current: $1.92
Upside: +525.00%
Jul 7, 2022
Maintains: Buy
Price Target: $16 → $8
Current: $2.00
Upside: +300.00%
Feb 9, 2022
Maintains: Buy
Price Target: $12,320 → $4,928
Current: $5.90
Upside: +83,425.42%